Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Allergy Clin Immunol ; 128(5): 1086-92.e1-3, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21762978

RESUMO

BACKGROUND: IL-5 plays a central role in the development and maintenance of eosinophilia (EO) and eosinophil activation in a wide variety of eosinophilic disorders. Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor α (IL-5Rα) on eosinophils in vitro, little is known about soluble and surface IL-5Rα levels in vivo. OBJECTIVE: To assess soluble and surface IL-5Rα levels in patients with EO and/or mastocytosis. METHODS: Surface IL-5Rα expression was assessed by flow cytometry in blood and/or bone marrow from subjects with EO (n = 39) and systemic mastocytosis (n = 8) and from normal volunteers (n = 28). Soluble IL-5Rα (sIL-5Rα) level was measured in a cohort of 177 untreated subjects and correlated with EO, eosinophil activation, and serum tryptase and cytokine levels. RESULTS: IL-5Rα expression on eosinophils inversely correlated with EO (r = -0.48; P < .0001), whereas serum levels of sIL-5Rα increased with the eosinophil count (r = 0.56; P < .0001) and serum IL-5 (r = 0.40; P < .0001) and IL-13 (r = 0.29; P = .004) levels. Of interest, sIL-5Rα level was significantly elevated in patients with systemic mastocytosis without EO. Although sIL-5Rα levels correlated with serum tryptase levels in these patients, eosinophil activation, assessed by CD69 expression on eosinophils and serum eosinophil-derived neurotoxin levels, was increased compared with that in normal subjects. CONCLUSIONS: These data are consistent with an in vivo IL-5Rα regulatory pathway in human eosinophils similar to that described in vitro and involving a balance between soluble and surface receptor levels. This may have implications with respect to the use of novel therapeutic agents targeting IL-5 and its receptor in patients with EO and/or mastocytosis.


Assuntos
Eosinofilia/metabolismo , Subunidade alfa de Receptor de Interleucina-5/biossíntese , Mastocitose Sistêmica/metabolismo , Adulto , Idoso , Separação Celular , Citocinas/análise , Citocinas/biossíntese , Citocinas/imunologia , Ensaio de Imunoadsorção Enzimática , Neurotoxina Derivada de Eosinófilo/análise , Neurotoxina Derivada de Eosinófilo/biossíntese , Neurotoxina Derivada de Eosinófilo/imunologia , Eosinofilia/imunologia , Eosinófilos/imunologia , Eosinófilos/metabolismo , Feminino , Citometria de Fluxo , Humanos , Subunidade alfa de Receptor de Interleucina-5/imunologia , Masculino , Mastocitose Sistêmica/imunologia , Pessoa de Meia-Idade , Triptases/sangue , Adulto Jovem
3.
JCI Insight ; 4(8)2019 04 18.
Artigo em Inglês | MEDLINE | ID: mdl-30996141

RESUMO

Cystic fibrosis (CF) is characterized by increased mucus viscosity and delayed mucociliary clearance that contributes to progressive decline of lung function. Mucus in the respiratory and GI tract is excessively adhesive in the presence of airway dehydration and excess extracellular Ca2+ upon mucin release, promoting hyperviscous, densely packed mucins characteristic of CF. Therapies that target mucins directly through ionic interactions remain unexploited. Here we show that poly (acetyl, arginyl) glucosamine (PAAG), a polycationic biopolymer suitable for human use, interacts directly with mucins in a Ca2+-sensitive manner to reduce CF mucus viscoelasticity and improve its transport. Notably, PAAG induced a linear structure of purified MUC5B and altered its sedimentation profile and viscosity, indicative of proper mucin expansion. In vivo, PAAG nebulization improved mucociliary transport in CF rats with delayed mucus clearance, and cleared mucus plugging in CF ferrets. This study demonstrates the potential use of a synthetic glycopolymer PAAG as a molecular agent that could benefit patients with a broad array of mucus diseases.


Assuntos
Fibrose Cística/tratamento farmacológico , Glucosamina/análogos & derivados , Mucina-5B/metabolismo , Depuração Mucociliar/efeitos dos fármacos , Muco/efeitos dos fármacos , Polímeros/farmacologia , Animais , Fibrose Cística/genética , Fibrose Cística/patologia , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Modelos Animais de Doenças , Furões , Glucosamina/farmacologia , Glucosamina/uso terapêutico , Humanos , Camundongos , Camundongos Endogâmicos CFTR , Mucina-5B/química , Muco/metabolismo , Polímeros/uso terapêutico , Estrutura Quaternária de Proteína/efeitos dos fármacos , Ratos , Mucosa Respiratória/efeitos dos fármacos , Mucosa Respiratória/patologia , Viscosidade/efeitos dos fármacos
4.
Mol Biol Cell ; 25(19): 3081-93, 2014 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-25103245

RESUMO

Human Period 2 (hPer2) is a transcriptional regulator at the core of the circadian clock mechanism that is responsible for generating the negative feedback loop that sustains the clock. Its relevance to human disease is underlined by alterations in its function that affect numerous biochemical and physiological processes. When absent, it results in the development of various cancers and an increase in the cell's susceptibility to genotoxic stress. Thus we sought to define a yet-uncharacterized checkpoint node in which circadian components integrate environmental stress signals to the DNA-damage response. We found that hPer2 binds the C-terminal half of human p53 (hp53) and forms a stable trimeric complex with hp53's negative regulator, Mdm2. We determined that hPer2 binding to hp53 prevents Mdm2 from being ubiquitinated and targeting hp53 by the proteasome. Down-regulation of hPer2 expression directly affects hp53 levels, whereas its overexpression influences both hp53 protein stability and transcription of targeted genes. Overall our findings place hPer2 directly at the heart of the hp53-mediated response by ensuring that basal levels of hp53 are available to precondition the cell when a rapid, hp53-mediated, transcriptional response is needed.


Assuntos
Relógios Circadianos/genética , Proteínas Circadianas Period/metabolismo , Proteínas Proto-Oncogênicas c-mdm2/metabolismo , Ativação Transcricional/genética , Proteína Supressora de Tumor p53/metabolismo , Proteínas 14-3-3/genética , Biomarcadores Tumorais/genética , Proteínas de Ciclo Celular/genética , Ritmo Circadiano/genética , Inibidor de Quinase Dependente de Ciclina p21/genética , Dano ao DNA , Reparo do DNA , Exorribonucleases/genética , Regulação da Expressão Gênica , Células HCT116 , Humanos , Complexos Multiproteicos/metabolismo , Proteínas Nucleares/genética , Proteínas Circadianas Period/biossíntese , Ligação Proteica , Transcrição Gênica , Proteína Supressora de Tumor p53/biossíntese , Proteína Supressora de Tumor p53/genética , Ubiquitinação
5.
Mol Cell Biol ; 28(15): 4697-711, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18505821

RESUMO

Although efforts have been made to identify circadian-controlled genes regulating cell cycle progression and cell death, little is known about the metabolic signals modulating circadian regulation of gene expression. We identify heme, an iron-containing prosthetic group, as a regulatory ligand controlling human Period-2 (hPer2) stability. Furthermore, we define a novel heme-regulatory motif within the C terminus of hPer2 (SC(841)PA) as necessary for heme binding and protein destabilization. Spectroscopy reveals that whereas the PAS domain binds to both the ferric and ferrous forms of heme, SC(841)PA binds exclusively to ferric heme, thus acting as a redox sensor. Consequently, binding prevents hPer2 from interacting with its stabilizing counterpart cryptochrome. In vivo, hPer2 downregulation is suppressed by inhibitors of heme synthesis or proteasome activity, while SA(841)PA is sufficient to stabilize hPer2 in transfected cells. Moreover, heme binding to the SC(841)PA motif directly impacts circadian gene expression, resulting in altered period length. Overall, the data support a model where heme-mediated oxidation triggers hPer2 degradation, thus controlling heterodimerization and ultimately gene transcription.


Assuntos
Ritmo Circadiano/efeitos dos fármacos , Heme/farmacologia , Proteínas Nucleares/química , Proteínas Nucleares/metabolismo , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Fatores de Transcrição/química , Fatores de Transcrição/metabolismo , Motivos de Aminoácidos , Sequência de Aminoácidos , Animais , Células CHO , Ritmo Circadiano/genética , Dicroísmo Circular , Cricetinae , Cricetulus , Criptocromos , Dimerização , Flavoproteínas/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Células HeLa , Humanos , Dados de Sequência Molecular , Oxirredução/efeitos dos fármacos , Proteínas Circadianas Period , Ligação Proteica/efeitos dos fármacos , Estrutura Terciária de Proteína , Termodinâmica
6.
JBC j. bras. clin. odontol. integr ; 5(30): 503-506, dez. 2001-jan. 2002. ilus
Artigo em Português | LILACS, BBO - odontologia (Brasil) | ID: lil-336405

RESUMO

O presente trabalho tem como objetivo apresentar um caso clínico de resoluçäo estética anterior, utilizando uma prótese fixa adesiva livre de metal, confeccionada com resina composta laboratorial, reforçada com fibras


Assuntos
Humanos , Masculino , Prótese Parcial Fixa , Prótese Adesiva , Estética Dentária
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA